Cipla unit's US facility receives 5 observations from American drug regulator; shares fall

Cipla shares remained under pressure on Thursday, after the US drug regulator issued five observations about a New York-based facility of the company's wholly-owned subsidiary, InvaGen Pharmaceuticals. The Cipla stock declined by as much as Rs 35, or 2.8 per cent, to Rs 1,203.9 apiece on BSE in an overall weak Mumbai market, before settling at Rs 1,209.9 apiece for the day. 

In a regulatory filing post-market hours on Wednesday, Cipla said the US Food and Drug Administration (USFDA) conducted a "routine current good manufacturing practices (cGMP)" inspection at InvaGen Pharmaceuticals' manufacturing facility located in Central Islip in Long Island, New York, from September 11 to September 19. The regulator also conducted a pre-approval inspection for a site transfer product within InvaGen. 

After the completion of the inspection, InvaGen received five observations in Form 483 from the FDA. "There are no repeat or data integrity (DI) observations. The Company will work closely with the USFDA and is committed to addressing these comprehensively within stipulated time," the filing added.  

TRENDING NOW

VC firm GVFL joins hands with Brinc to launch multi-sector startup accelerator

Tremors felt in Bengal as 5.6 magnitude earthquake hits Bangladesh

OpenAI postpones GPT store launch to 2024

Sam Altman's Q* Project and WorldCoin: Evaluating the potential threat to humanity

Google resolves unfair employee practices lawsuit with $27 million settlement

GST collection rises to Rs 1.67,929 lakh crore in November, records highest growth rate of 15% Y-o-Y

Amazon signs 3 launches with Musk's SpaceX to support 'Project Kuiper'

Brand Retention | 82% of existing Lava users likely to purchase next smartphone from same brand: Report

Animal box office collection Day 1: Ranbir Kapoor's movie earns Rs 116 crore

D-Street Newsmakers: Flair Writing, New India Assurance, Ashok Leyland among 10 stocks that hogged limelight today

India, Africa to be major contributors to 112 million barrel/day of peak global crude oil demand in 2030: S&P

Protect your WhatsApp chats using secret code - Here's how

Ukraine plans to produce 100-km-range air defence systems

Nothing Phone (2) price drop alert! Get flat Rs 5,000 discount - Check details

COVID-19 Update: India records 88 new cases & 396 active cases

Form 483, also known as the notice of inspectional observations, is issued at the end of an inspection by the US health regulator in cases where the field authorities come across deficiencies in quality systems, or find conditions violating food and drug safety laws.    

(This story will be updated shortly)

Catch latest stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.